$1.19 Billion is the total value of Alphabet Inc.'s 17 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 72.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JD | New | JD com Incspon adr cl a | $527,908,000 | – | 13,553,474 | +100.0% | 44.35% | – |
| ARRS | Arris Intl Inc | $237,202,000 | -8.0% | 9,703,500 | 0.0% | 19.93% | -52.5% | |
| ZS | Zscaler Inc | $99,691,000 | +27.4% | 2,788,560 | 0.0% | 8.37% | -34.2% | |
| DOCU | New | DocuSign Inc | $77,366,000 | – | 1,461,106 | +100.0% | 6.50% | – |
| RCUS | Arcus Biosciences Inc | $61,809,000 | -20.7% | 5,049,786 | 0.0% | 5.19% | -59.1% | |
| MGTA | New | Magenta Therapeutics Inc | $45,078,000 | – | 3,339,138 | +100.0% | 3.79% | – |
| SNAP | Snap Inccl a | $34,277,000 | -17.5% | 2,618,548 | 0.0% | 2.88% | -57.4% | |
| FTSV | New | Forty Seven Inc | $24,735,000 | – | 1,545,966 | +100.0% | 2.08% | – |
| AUTL | New | Autolus Therapeutics PLCspon ads | $19,130,000 | – | 714,072 | +100.0% | 1.61% | – |
| SPRO | Spero Therapeutics Inc | $16,320,000 | +2.9% | 1,112,473 | 0.0% | 1.37% | -46.8% | |
| EVLO | New | Evelo Biosciences Inc | $12,514,000 | – | 1,060,495 | +100.0% | 1.05% | – |
| CLDR | Sell | Cloudera Inc | $11,668,000 | -49.1% | 855,420 | -19.4% | 0.98% | -73.7% |
| ASNS | Arsanis Inc | $9,831,000 | -84.1% | 451,362 | 0.0% | 0.83% | -91.8% | |
| DNLI | Sell | Denali Therapeutics Inc | $8,180,000 | -26.7% | 536,411 | -5.3% | 0.69% | -62.1% |
| PS | New | Pluralsight Inccl a | $2,480,000 | – | 101,442 | +100.0% | 0.21% | – |
| SQ | Square Inccl a | $1,812,000 | +25.3% | 29,400 | 0.0% | 0.15% | -35.3% | |
| DBX | Dropbox Inccl a | $423,000 | +3.9% | 13,033 | 0.0% | 0.04% | -45.5% | |
| ARMO | Exit | Armo Biosciences Inc | $0 | – | -1,214,700 | -100.0% | -7.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPERO THERAPEUTICS INC | 24 | Q3 2023 | 3.5% |
| AUTOLUS THERAPEUTICS PLC | 22 | Q3 2023 | 2.8% |
| Magenta Therapeutics Inc. | 21 | Q2 2023 | 3.8% |
| DEXCOM INC | 20 | Q3 2023 | 17.4% |
| Evelo Biosciences Inc. | 20 | Q1 2023 | 1.6% |
| ALECTOR INC | 19 | Q3 2023 | 1.1% |
| Lyft Inc | 18 | Q2 2023 | 51.9% |
| QUINCE THERAPEUTICS INC | 18 | Q3 2023 | 0.6% |
| Arcus Biosciences Inc | 17 | Q1 2022 | 12.7% |
| FULCRUM THERAPEUTICS INC | 17 | Q3 2023 | 0.7% |
View Alphabet Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ARRIS International plc | February 14, 2019 | 7,603,500 | 4.4% |
View Alphabet Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-04-30 |
| 4 | 2024-04-30 |
| 10-Q | 2024-04-26 |
| 144 | 2024-04-26 |
| 4 | 2024-04-26 |
| 4 | 2024-04-26 |
| ARS | 2024-04-26 |
| DEF 14A | 2024-04-26 |
| DEFA14A | 2024-04-26 |
| 8-K | 2024-04-25 |
View Alphabet Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.